The More I Look at (MDCX), the More I Can’t Wait for Today’s Session to Start

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Medicus Pharma Ltd. Paul Prescott Just Put Medicus Pharma Ltd. (NASDAQ: MDCX) in the Top Spot on His Watchlist This Morning—Wednesday, April 15, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. My Full Coverage On (MDCX) Begins Right Now Make Sure (MDCX) is On Your Screen While It’s Still Early… April 15, 2026 The More I Look at (MDCX), the More I Can’t Wait for Today’s Session to Start Dear Reader, Every so often, a new idea challenges something that’s long been accepted as the default. For one of the most common forms of skin cancer, the usual path has typically involved surgical removal. It’s familiar. It’s established. But it’s not the only approach being explored anymore. In recent clinical work, a localized patch-based delivery system has shown the ability to target lesions directly, with Phase 2 results indicating clinical clearance in a portion of patients at higher doses. That’s exactly the kind of shift Street Ideas is designed to discover early… and it brings Medicus Pharma Ltd. (NASDAQ: MDCX) into focus. And that’s why (MDCX) just climbed to the top of our watchlist this morning—Wednesday, April 15, 2026. But keep in mind, one analyst has a target on (MDCX) that you’ll want to see. Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $6 target on (MDCX) which suggests 1,400% upside potential from its recent $.40 range. Headquartered in Philadelphia, Medicus Pharma Ltd. (NASDAQ: MDCX) operates with a distinct capital-efficient model designed to accelerate the clinical programs of disruptive therapeutic assets. Rather than bearing the massive costs of late-stage global commercialization, the company’s stated strategy is to advance select candidates through Phase 2 clinical proof-of-concept and subsequently pursue high-value licensing or strategic partnerships with established pharmaceutical firms. This model is currently being tested through two primary therapeutic pillars: the SkinJect™ platform for dermatology and oncology, and the Teverelix hormone-suppression program. Dermatology Pillar: SkinJect™ and the D-MNA Platform The company's lead asset, SkinJect™ (D-MNA), is a novel localized immuno-oncology precision product. It utilizes a patented dissolvable microneedle patch to deliver doxorubicin directly into basal cell carcinoma (BCC) lesions. This non-invasive delivery method aims to provide a viable alternative to surgical resection, which can often be disfiguring for patients with multiple or recurrent lesions. Phase 2 Milestones: In December 2025, Medicus successfully completed enrollment of 90 patients in its U.S.-based randomized, double-blind Phase 2 study (SKNJCT-003). Topline Data Validation: Topline results released in early 2026 revealed highly promising results, particularly in the highest dose (200ug) cohort, which showed up to a 73% clinical clearance rate. Surgical Avoidance: Key opinion leaders have highlighted that the data suggests approximately 3 out of 4 patients treated with the optimal dose may avoid immediate surgery. Regulatory Path: Following a Type C meeting with the FDA, the company is pursuing a potential 505(b)(2) regulatory pathway, which could significantly compress the time to market. Hormone-Suppression Pillar: Teverelix In August 2025, Medicus significantly expanded its portfolio by acquiring Antev, a UK-based biotech developing Teverelix. Teverelix is a next-generation long-acting GnRH antagonist designed to suppress sex hormone production without the initial "testosterone flare" associated with legacy GnRH agonists. Cardiovascular Safety: The mechanism of Teverelix is particularly beneficial for high-risk cardiovascular patients with advanced prostate cancer, as it reduces the physiological stress caused by hormonal surges. Recent FDA Clearance: In February 2026, the company received "study may proceed" clearance to initiate its Phase 2b dose-optimization study in men with advanced prostate cancer. Optimized Royalty Structure: To enhance the drug’s long-term economic profile, Medicus successfully reduced the royalty rate payable on worldwide net sales from approximately 4% down to 2%. The Agentic AI Strategy: Scaling Through Simulation A unique differentiator for Medicus is its integration of agentic AI-driven clinical development capabilities. In December 2025, the firm entered into a collaboration with Reliant AI Inc. to develop a platform optimized for: Protocol Simulation: Testing trial designs in a virtual environment before patient enrollment. Dynamic Site Selection: Identifying geographic locations with the highest concentration of target patient populations to accelerate enrollment. Patient Stratification: Utilizing pharmacodynamic-informed data to ensure the most responsive participants are prioritized, thereby de-risking the clinical outcome. Financial and Market Metrics Medicus enters the second quarter of 2026 with a market capitalization of approximately $16M and a cash position of $8.7M as of Q2 2026. During fiscal year 2025, the company successfully raised approximately $31.9M in total financing proceeds to fund its accelerated Phase 2 programs. While the company currently reports a net loss consistent with high-growth biotech development ($47.3M for FY2025), management emphasizes that their capital-efficient model is focused on near-term value creation through proof-of-concept readouts rather than a long-term cash-intensive commercial build-out. What’s Putting (MDCX) on the Radar April 06, 2026 Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention April 01, 2026 Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset March 30, 2026 Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate March 26, 2026 Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan March 16, 2026 Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 March 09, 2026 Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset March 05, 2026 Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200µg Cohort March 03, 2026 Medicus Pharma To Participate in the 38th Annual Roth Conference February 10, 2026 Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk Here’s What Has (MDCX) Topping Our Watchlist This Morning: 7 Reasons to Watch It Today—Wednesday, April 15, 2026 1. Street Target: one biotechnology analyst has published a $6 target on (MDCX), which suggests 1,400% upside potential from its recent $.40 range. 2. Clearance Momentum: recent Phase 2 data showed that (MDCX) achieved up to a 73% clinical clearance rate in higher dose cohorts, indicating measurable biological activity. 3. Precision Delivery: a localized microneedle delivery system being developed by (MDCX) is designed to target lesions directly, offering a potential alternative to traditional surgical procedures. 4. Pipeline Depth: the addition of Teverelix gives (MDCX) exposure to a second therapeutic area focused on hormone suppression without the initial flare seen in older approaches. 5. FDA Clearance: a recent “study may proceed” clearance allows (MDCX) to move forward with a Phase 2b study in advanced prostate cancer patients. 6. Partner-Focused Model: rather than building a full commercial infrastructure, (MDCX) is structured to advance programs through Phase 2 and pursue licensing or strategic partnerships. 7. AI Advantage: a collaboration with Reliant AI positions (MDCX) to use simulation and data-driven tools to optimize trial design and patient selection. Make Sure (MDCX) is On Your Screen While It’s Still Early… Sometimes it’s not just one factor—it’s how multiple ideas start aligning at the same time. Here, you have a localized microneedle system showing encouraging Phase 2 results, including clinical clearance in a meaningful portion of patients at higher doses. You also have a second program progressing with FDA clearance, aimed at addressing hormone-related conditions without the initial flare seen in older methods. Behind that, there’s a model focused on advancing programs through key clinical milestones and seeking strategic partnerships, combined with AI tools designed to improve how trials are structured and executed. And when you add in an analyst target of $6—which suggests 1,400% upside potential from its recent $0.40 range—it becomes clear why this name is starting to draw more attention. (MDCX) is shaping up to be a name we’ll be tracking from the opening bell this morning. Make sure (MDCX) is up on your screen right now. Also, watch for my next update, it could be hitting any moment. Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter   Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, 147 Media LLC has been paid seventy eight thousand eight hundred USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither 147 Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://street-ideas.com/disclosure/mdcx-7E33I/#details

Street Ideas | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by paul@street-ideas.com